Jamieson Wellness Eyes Record Year as Investors Await 2025 Results

TORONTO, ON – February 12, 2026 – Jamieson Wellness Inc. (TSX:JWEL) is poised to reveal the full measure of its 2025 performance, with investors and market analysts keenly awaiting the release of its fourth-quarter and full-year financial results on February 26, 2026. The announcement will serve as a crucial report card on the vitamin and supplement giant's ambitious global strategy, which has focused on aggressive expansion in China, deeper penetration into the U.S. market, and continuous product innovation.

The upcoming figures will be measured against a robust 2025 guidance that the company confidently narrowed following a strong third quarter. With a path to surpassing $1 billion in annual revenue in sight, the results will provide critical insight into the company's momentum heading into 2026 and its ability to capitalize on enduring global health and wellness trends.

A Year of Strategic Execution and Global Growth

Throughout 2025, Jamieson Wellness has been defined by the execution of a multi-pronged growth strategy. A central pillar has been the continued integration and expansion of the youtheory brand, acquired in 2022 to establish a significant foothold in the competitive U.S. market. The company projected 8.0% to 12.0% revenue growth for youtheory in fiscal 2025, driven by strong e-commerce performance and new product launches that are resonating with American consumers.

Even more striking has been the company's phenomenal success in China. The market has become Jamieson's fastest-growing and highest-margin region. Leveraging sophisticated digital marketing campaigns on platforms like Douyin, where it was named 'Store of the Year', and engaging wellness influencers, Jamieson has deeply embedded its brand with Chinese consumers. Following nearly 80% growth in 2024, the company projected an additional 45.0% to 50.0% revenue growth from China in 2025, a figure that will be under intense scrutiny in the upcoming report.

This international push has been supported by a steady stream of product innovation. The launch of new items, such as an Ashwagandha gummy and new magnesium formulations, has successfully tapped into consumer demand for stress relief and targeted health solutions. These innovations have contributed to growth not only in North America but also in other international markets, which were expected to grow by 20.0% to 25.0% for the year.

Decoding the Financial Outlook

Investors will be looking for Jamieson to meet or exceed its own financial benchmarks. After its third-quarter results, the company updated its full-year guidance for fiscal 2025, projecting consolidated revenue between $810.0 million and $830.0 million, which would represent growth of 10.4% to 13.1%. The forecast for adjusted EBITDA was set between $158.0 million and $162.0 million, with adjusted diluted earnings per share (EPS) expected to land between $1.82 and $1.88.

The context for this anticipation was set by the third quarter of 2025, which saw consolidated revenue climb 13.2% year-over-year. While the top-line growth was impressive, the company's stock saw a minor dip after the announcement, as earnings per share slightly missed analyst consensus. This highlights the market's sensitivity and the high expectations placed on the company.

A key metric to watch will be the gross profit margin. In Q3 2025, the margin expanded by a significant 350 basis points. Management attributed this primarily to the sales mix, with a higher proportion of revenue coming from the high-margin Jamieson Brands segment, particularly its booming China business. Continued margin strength in the fourth quarter would signal the financial benefits of its brand-focused international strategy.

Tapping into Global Wellness Trends

Jamieson's performance serves as a barometer for the broader Vitamins, Minerals, and Supplements (VMS) industry. The company's success is directly tied to powerful consumer trends, including a post-pandemic surge in health consciousness and a growing preference for natural, clean-label products. The global market for natural health supplements was projected to reach nearly US$67 billion in 2025, and Jamieson's "Canadian-made" marketing and emphasis on quality have helped it capture a loyal customer base.

The company has also adeptly responded to the demand for new and more convenient product formats. The growth of its gummy and powder products aligns with an industry-wide shift away from traditional pills. Furthermore, its product development pipeline is increasingly focused on addressing specific consumer needs, from immunity and stress management to solutions for an aging population, which is a key demographic driver in Canada and other developed markets.

However, the industry is not without its challenges. Persistent inflation and economic pressures are forcing consumers to be more selective with their spending. While the demand for wellness products remains resilient, value and proven efficacy are becoming more important purchasing factors. Jamieson's ability to maintain its premium brand positioning while demonstrating value will be crucial for sustained growth.

A Tale of Two Segments

A closer look at Jamieson's business reveals a strategic pivot that is reshaping its financial profile. The company operates through two main segments: the high-growth Jamieson Brands segment and the Strategic Partners division, which handles contract manufacturing for other companies.

The Jamieson Brands segment—encompassing the flagship Jamieson brand in Canada, the U.S.-focused youtheory, and its international operations—is the clear engine of growth. This segment saw revenue jump 16.5% in the third quarter and was projected to grow between 12.9% and 15.3% for the full year. It represents the company's core strategic focus and its future.

In contrast, the Strategic Partners segment has been in a planned decline, with revenue expected to decrease by approximately 5.0% in 2025. This is the result of a deliberate strategy to prioritize the company's own higher-margin brands over lower-margin contract manufacturing. While this shift results in a top-line headwind from one part of the business, it is a key driver of the improved profitability and gross margin expansion that has excited investors. The upcoming results will confirm how effectively this transition was managed through the end of the year. When the company hosts its investor call, all eyes will be on the 2026 outlook and management's commentary on the sustainability of its remarkable growth in China and its continued progress in the U.S. market.